Bloomberg the Company

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Summit Corp PLC

+ Add to Watchlist


127.0000 GBp 5.0000 4.10%

As of 11:30:00 ET on 01/29/2015.

Snapshot for Summit Corp PLC (SUMM)

Open: 122.0000 Day's Range: 122.0000 - 127.0000 Volume: 82,797
Previous Close: 122.0000 52wk Range: 101.2500 - 237.5000 1-Yr Rtn: -42.92%

Stock Chart for SUMM

No chart data available.
  • SUMM:LN 127.0000
  • 1D
  • 1M
  • 1Y
Interactive SUMM Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SUMM

Current P/E Ratio (ttm) -
Estimated P/E(01/2015) -
Relative P/E vs. UKX -
Earnings Per Share (GBP) (ttm) -0.3271
Est. EPS (GBP) (01/2015) -0.2770
Est. PEG Ratio -
Market Cap (M GBP) 52.22
Shares Outstanding (M) 41.12
30 Day Average Volume 32,116
Price/Book (mrq) 52.1454
Price/Sale (ttm) 24.0522
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/29/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SUMM

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for SUMM

Summit Corporation plc is a drug discovery and development Company targeting areas of high unmet medical need. The Company is advancing two clinical-stage programmes: Utrophin modulators for the treatment of all genetic forms of the fatal disease, Duchenne Muscular Dystrophy, and a novel antibiotic for the selective treatment of infections caused by C. difficile bacteria.

Glyn O EdwardsChief Executive OfficerErik OstrowskiChief Financial Officer
More Company Profile & Key Executives for SUMM

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil